PMGC Holdings Inc Dossier
Qualitative Analysis
Business overview
PMGC Holdings Inc. (NASDAQ: ELAB), formerly known as Elevai Labs, Inc., is a diversified holding company headquartered in Newport Beach, California. Originally incorporated in 2020 as a physician-dispensed skincare company, the firm rebranded in December 2024 and pivoted toward a multi-subsidiary platform. Today, PMGC operates across three primary segments: corporate, treasury, and biosciences; IT packaging solutions; and precision engineering and machining. Its biopharmaceutical subsidiary, NorthStrive Biosciences, is developing EL-22 and EL-32, which are first-in-class engineered probiotics designed to preserve lean muscle mass during GLP-1 receptor agonist-based weight loss treatments. Concurrently, PMGC is executing an aggressive roll-up strategy in the U.S. precision manufacturing sector, acquiring AS9100D-certified and ITAR-registered CNC machining businesses that serve mission-critical aerospace, defense, and space exploration supply chains.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Assembling a domestic precision manufacturing platform of AS9100D-certified CNC machining businesses serving the aerospace, defense, and industrial end markets to capitalize on reshoring and supply chain security trends.
Expected impact: Diversifying the company's portfolio into cash-flowing, high-barrier industrial verticals with established blue-chip customer bases.
Identifying, acquiring, and commercializing advanced defense technologies, with a specific focus on uncrewed, autonomous, and multi-domain drone systems.
Expected impact: Establishing a commercial gateway for dual-use defense technologies and positioning the company for future contracts with the Department of Defense and the Navy.
Expanding the intellectual property portfolio of subsidiary NorthStrive Biosciences from animal health and agricultural applications into human pharmaceutical applications, specifically targeting muscle preservation during GLP-1 and obesity treatments.
Expected impact: Securing proprietary positions for compounds EL-22 and EL-32 in high-growth obesity and metabolic health markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand PMGC's aerospace manufacturing platform and precision CNC machining capabilities. A&B Aerospace is an AS9100D-certified contractor serving Tier 1 customers like Boeing, Honeywell, and Moog.
Financial impact: Adds approximately $5.0 million in TTM revenue and $610,000 in management-adjusted EBITDA (as of February 28, 2026) to PMGC's consolidated financials.
Acquisition of a Northern California-based precision machining and manufacturing services company serving medical, aerospace, biotech, semiconductor, and transportation markets.
Financial impact: Contributed to the company's record Q1 2026 revenue of approximately $682,000.
Strategic Partnerships
Updates development milestones and timelines for pre-clinical trials and Investigational New Drug (IND) application events for biopharmaceutical assets managed by NorthStrive Biosciences.
Terms: PMGC provides monetary consideration to MOA payable upon execution and within 30 days after the March 24, 2026 effective date.